Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.
Monday, the FDA cleared the British drugmaker’s Imfinzi—in tandem with standard-of-care chemo—for use in previously untreated patients with extensive-stage small cell lung cancer. About 15% of all lung cancer cases are small cell, a fast-growing form of the disease.
Image: The new indication for AZ's Imfinzi could help it rack up $413 in U.S. sales, SVB Leerink analysts have estimated. (AstraZeneca)